Physician profile
Durga K Mulpuri
NPI 1891786216
$2,478.94
in general payments reported to CMS, 2019-2025
21 companies · $1,139 in 2025
The $1,139 reported for 2025 was more than what 88% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $384 · 2020: $12.80 · 2021: $39.59 · 2022: $35.53 · 2023: $264 · 2024: $605 · 2025: $1,139.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,007.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,007.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,048.99 | 2019-2025 | Wegovy, Saxenda, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $550.69 | 2019-2025 | Breztri, Farxiga, Airsupra |
| Glaxosmithkline, LLC. | $132.28 | 2019-2025 | Trelegy Ellipta, Arexvy |
| Pfizer INC. | $119.59 | 2019-2025 | |
| Amgen INC. | $92.01 | 2019-2025 | Repatha, Otezla, Prolia |
| Lilly USA, LLC | $75.29 | 2025 | Mounjaro |
| Bayer Healthcare Pharmaceuticals INC. | $56.12 | 2024-2025 | |
| Abbvie INC. | $54.63 | 2019-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $52.45 | 2023-2025 | Jardiance |
| Abbott Laboratories | $51.19 | 2021-2025 | Freestyle Libre 3 |
| Exact Sciences Corporation | $44.70 | 2024-2025 | Cologuard Collection Kit |
| Shield Therapeutics INC | $30.64 | 2023 | Accrufer |
| Takeda Pharmaceuticals U.S.A., INC. | $27.24 | 2019 | |
| Novartis Pharmaceuticals Corporation | $25.19 | 2019 | |
| Dexcom, INC. | $22.91 | 2025 | Dexcom G6 Transmitter |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $19.69 | 2024 | Vaxelis, Gardasil 9, Gardasil |
| Phathom Pharmaceuticals, INC. | $17.93 | 2024 | Voquezna |
| Currax Pharmaceuticals LLC | $15.87 | 2025 | Contrave |
| Janssen Pharmaceuticals, INC | $15.42 | 2019 | |
| Gilead Sciences, INC. | $14.61 | 2025 | |
| E.R. Squibb & Sons, L.L.C. | $11.50 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Durga Mulpuri listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.